BMS to acquire Forbius in oncology expansion

Bristol Myers Squibb (BMS) has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Sigmapharm to appeal Pfizer and BMS’ Eliquis win

3 September 2020 Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.

Americas

BMS partners with drug accelerator to launch biotech

5 February 2020 Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

Americas

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

More on this story

Generics

Sigmapharm to appeal Pfizer and BMS’ Eliquis win

3 September 2020 Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.

Americas

BMS partners with drug accelerator to launch biotech

Americas

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

More on this story

Generics

Sigmapharm to appeal Pfizer and BMS’ Eliquis win

3 September 2020 Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.

Americas

BMS partners with drug accelerator to launch biotech

Americas

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.